Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026)

Jazz Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $2.2 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 83.75% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (up 83.75% YoY), while the FY2025 annual figure was $2.2 billion, up 115.92% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.2 billion, roughly flat from $2.2 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $2.3 billion in Q3 2025, with the low at $705.4 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $1.2 billion (2025), against an average of $1.4 billion.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 34.54% in 2024, then surged 120.79% in 2025.
• Jazz Pharmaceuticals' Total Current Liabilities stood at $933.2 million in 2022, then jumped by 64.67% to $1.5 billion in 2023, then tumbled by 32.42% to $1.0 billion in 2024, then soared by 115.92% to $2.2 billion in 2025, then increased by 0.18% to $2.2 billion in 2026.
• Business Quant data shows JAZZ's Total Current Liabilities at $2.2 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.3 billion in Q3 2025.